Patent classifications
C07D213/71
Heterocyclic compound
A compound of formula (I), or an N-oxide thereof is provided. In the compound of formula (I), Het.sup.1 represents Het.sup.1-1, Het.sup.1-2, Het.sup.1-3, Het.sup.1-4, Het.sup.1-5, Het.sup.1-6, Het.sup.1-7, Het.sup.1-8, or Het.sup.1-9, and the remaining variable groups are as defined in the specification. The compound of formula (I), or N-oxide thereof has a superior effect in controlling arthropod pests. ##STR00001##
Pesticidally active heterocyclic derivatives with sulphur containing substituents
Compounds of formula I(I), wherein the substituents are as defined in claim 1, and the agrochemically acceptable salts, stereoisomers, enantiomers, tautomers and N-oxides of those compounds, can be used as insecticides and can be prepared in a manner known per se. ##STR00001##
COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY
In one aspect, compounds of Formula AA, or a pharmaceutically acceptable salt thereof, are featured. The variables shown in Formula AA are as defined in the claims. The compounds of formula AA are NLRP3 activity modulators and, as such, can be used in the treatment of metabolic disorders (e.g. Type 2 diabetes, atherosclerosis, obesity or gout), a disease of the central nervous system (e.g. Alzheimer's disease, multiple sclerosis, Amyotrophic Lateral Sclerosis or Parkinson's disease), lung disease (e.g. asthma, COPD or pulmonary idiopathic fibrosis), liver disease (e.g. NASH syndrome, viral hepatitis or cirrhosis), pancreatic disease (e.g. acute pancreatitis or chronic pancreatitis), kidney disease (e.g. acute kidney injury or chronic kidney injury), intestinal disease (e.g. Crohn's disease or Ulcerative Colitis), skin disease (e.g. psoriasis), musculoskeletal disease (e.g. scleroderma), a vessel disorder (e.g. giant cell arteritis), a disorder of the bones (e.g. osteoarthritis, osteoporosis or osteopetrosis disorders), eye disease (e.g. glaucoma or macular degeneration), a disease caused by viral infection (e.g. HIV or AIDS), an autoimmune disease (e.g. Rheumatoid Arthritis, Systemic Lupus Erythematosus or Autoimmune Thyroiditis), cancer or aging.
##STR00001##
N-acyl-arylsulfonamide derivatives as aminoacyl-tRNA synthetase inhibitors
The present invention relates to novel N-acyl-diarysulfonamides acting as inhibitors of bacterial aminoacyl-tRNA synthetase. These can be used as medicines or as constituent of medicines for the treatment of bacterial infections. ##STR00001##
N-acyl-arylsulfonamide derivatives as aminoacyl-tRNA synthetase inhibitors
The present invention relates to novel N-acyl-diarysulfonamides acting as inhibitors of bacterial aminoacyl-tRNA synthetase. These can be used as medicines or as constituent of medicines for the treatment of bacterial infections. ##STR00001##
Modulators of the Cystic Fibrosis Transmembrane Conductance Regulator Protein and Methods of Use
- Robert J. Altenbach ,
- Andrew Bogdan ,
- Sylvain Couty ,
- Nicolas Desroy ,
- Gregory A. Gfesser ,
- Christopher Gaëtan Housseman ,
- Philip R. Kym ,
- Bo Liu ,
- Thi Thu Trang Mai ,
- Karine Fabienne Malagu ,
- Nuria Merayo Merayo ,
- Olivier Laurent Picolet ,
- Mathieu Rafaël Pizzonero ,
- Xenia B. Searle ,
- Steven Emiel Van der Plas ,
- Xueqing Wang ,
- Ming C. Yeung
The invention discloses compounds of Formula (I),
##STR00001##
wherein A.sup.1, R.sup.1, R.sup.2, R.sup.3, R.sup.4, and n are as defined herein. The present invention relates to compounds and their use in the treatment of cystic fibrosis, methods for their production, pharmaceutical compositions comprising the same, and methods of treating cystic fibrosis by administering a compound of the invention.
Modulators of the Cystic Fibrosis Transmembrane Conductance Regulator Protein and Methods of Use
- Robert J. Altenbach ,
- Andrew Bogdan ,
- Sylvain Couty ,
- Nicolas Desroy ,
- Gregory A. Gfesser ,
- Christopher Gaëtan Housseman ,
- Philip R. Kym ,
- Bo Liu ,
- Thi Thu Trang Mai ,
- Karine Fabienne Malagu ,
- Nuria Merayo Merayo ,
- Olivier Laurent Picolet ,
- Mathieu Rafaël Pizzonero ,
- Xenia B. Searle ,
- Steven Emiel Van der Plas ,
- Xueqing Wang ,
- Ming C. Yeung
The invention discloses compounds of Formula (I),
##STR00001##
wherein A.sup.1, R.sup.1, R.sup.2, R.sup.3, R.sup.4, and n are as defined herein. The present invention relates to compounds and their use in the treatment of cystic fibrosis, methods for their production, pharmaceutical compositions comprising the same, and methods of treating cystic fibrosis by administering a compound of the invention.
PROCESS OF MAKING CFTR MODULATORS
- Paul Angell ,
- John E. Cochran ,
- Benjamin J. Littler ,
- David Siesel ,
- Armando Urbina ,
- Corey Don ANDERSON ,
- Jeremy J. Clemens ,
- Thomas Cleveland ,
- Timothy Richard Coon ,
- Bryan Frieman ,
- Peter Grootenhuis ,
- Sara Sabina Hadida Ruah ,
- Jason McCartney ,
- Mark Thomas Miller ,
- Prasuna Paraselli ,
- Fabrice Pierre ,
- Sara E. Swift ,
- Jinglan Zhou
The disclosure provides processes for synthesizing Compound I, and pharmaceutically acceptable salts thereof.
##STR00001##
PROCESS OF MAKING CFTR MODULATORS
- Paul Angell ,
- John E. Cochran ,
- Benjamin J. Littler ,
- David Siesel ,
- Armando Urbina ,
- Corey Don ANDERSON ,
- Jeremy J. Clemens ,
- Thomas Cleveland ,
- Timothy Richard Coon ,
- Bryan Frieman ,
- Peter Grootenhuis ,
- Sara Sabina Hadida Ruah ,
- Jason McCartney ,
- Mark Thomas Miller ,
- Prasuna Paraselli ,
- Fabrice Pierre ,
- Sara E. Swift ,
- Jinglan Zhou
The disclosure provides processes for synthesizing Compound I, and pharmaceutically acceptable salts thereof.
##STR00001##
COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY
In one aspect, compounds of Formula AA, or a pharmaceutically acceptable salt thereof, are featured. The variables shown in Formula AA are as defined in the claims. The compounds of formula AA are NLRP3 activity modulators and, as such, can be used in the treatment of metabolic disorders (e.g. Type 2 diabetes, atherosclerosis, obesity or gout), a disease of the central nervous system (e.g. Alzheimer's disease, multiple sclerosis, Amyotrophic Lateral Sclerosis or Parkinson's disease), lung disease (e.g. asthma, COPD or pulmonary idiopathic fibrosis), liver disease (e.g. NASH syndrome, viral hepatitis or cirrhosis), pancreatic disease (e.g. acute pancreatitis or chronic pancreatitis), kidney disease (e.g. acute kidney injury or chronic kidney injury), intestinal disease (e.g. Crohn's disease or Ulcerative Colitis), skin disease (e.g. psoriasis), musculoskeletal disease (e.g. scleroderma), a vessel disorder (e.g. giant cell arteritis), a disorder of the bones (e.g. osteoarthritis, osteoporosis or osteopetrosis disorders), eye disease (e.g. glaucoma or macular degeneration), a disease caused by viral infection (e.g. HIV or AIDS), an autoimmune disease (e.g. Rheumatoid Arthritis, Systemic Lupus Erythematosus or Autoimmune Thyroiditis), cancer or aging.
##STR00001##